Limits...
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Beck CR, Convalescent Plasma Study Gro - J. Infect. Dis. (2014)

Bottom Line: Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset.Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14-.45; I(2) = 0%).Convalescent plasma may reduce mortality and appears safe.

View Article: PubMed Central - PubMed

Affiliation: East Midlands Centre, Public Health England.

Show MeSH

Related in: MedlinePlus

Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. aRecords were rejected for the following reasons: not population of interest, 12 records (1 in French, 1 in German, 1 in Italian, and 1 in Korean); no intervention of interest, 15 (1 in German); not suitable comparator, 1; nonhuman study, 1; and no outcome of interest, 7.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4264590&req=5

JIU396F1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. aRecords were rejected for the following reasons: not population of interest, 12 records (1 in French, 1 in German, 1 in Italian, and 1 in Korean); no intervention of interest, 15 (1 in German); not suitable comparator, 1; nonhuman study, 1; and no outcome of interest, 7.

Mentions: The search process yielded 3406 records (Figure 1). After sifting 1449 unique records against the protocol eligibility criteria, we identified 32 studies from 50 reports (Supplementary Table 1). Three studies could not be obtained [17–19], although results from a study by Bass et al [17] were reported elsewhere [20], which enabled their inclusion. French (n = 1), German (n = 2), and Korean (n = 2) records were screened by single reviewers because of a lack of multilingual collaborators.Figure 1.


The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Beck CR, Convalescent Plasma Study Gro - J. Infect. Dis. (2014)

Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. aRecords were rejected for the following reasons: not population of interest, 12 records (1 in French, 1 in German, 1 in Italian, and 1 in Korean); no intervention of interest, 15 (1 in German); not suitable comparator, 1; nonhuman study, 1; and no outcome of interest, 7.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4264590&req=5

JIU396F1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. aRecords were rejected for the following reasons: not population of interest, 12 records (1 in French, 1 in German, 1 in Italian, and 1 in Korean); no intervention of interest, 15 (1 in German); not suitable comparator, 1; nonhuman study, 1; and no outcome of interest, 7.
Mentions: The search process yielded 3406 records (Figure 1). After sifting 1449 unique records against the protocol eligibility criteria, we identified 32 studies from 50 reports (Supplementary Table 1). Three studies could not be obtained [17–19], although results from a study by Bass et al [17] were reported elsewhere [20], which enabled their inclusion. French (n = 1), German (n = 2), and Korean (n = 2) records were screened by single reviewers because of a lack of multilingual collaborators.Figure 1.

Bottom Line: Narrative analyses revealed consistent evidence for a reduction in mortality, especially when convalescent plasma is administered early after symptom onset.Exploratory post hoc meta-analysis showed a statistically significant reduction in the pooled odds of mortality following treatment, compared with placebo or no therapy (odds ratio, 0.25; 95% confidence interval, .14-.45; I(2) = 0%).Convalescent plasma may reduce mortality and appears safe.

View Article: PubMed Central - PubMed

Affiliation: East Midlands Centre, Public Health England.

Show MeSH
Related in: MedlinePlus